Cargando…
Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases
In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the onco...
Autores principales: | Zarogoulidis, Paul, Chinelis, Panos, Athanasiadou, Anastasia, Tsiouda, Theodora, Trakada, Georgia, Kallianos, Anastasios, Veletza, Lemonia, Hatzibougias, Dimitris, Mihalopoulou, Electra, Goupou, Eirini, Kosmidis, Christoforos, Sardeli, Chrysanthi, Huang, Haidong, Hohenforst-Schmidt, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519224/ https://www.ncbi.nlm.nih.gov/pubmed/28752057 http://dx.doi.org/10.1016/j.rmcr.2017.07.004 |
Ejemplares similares
-
Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
“Liquid elbows” due to afatinib administration
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
Endobronchial ultrasound convex probe for lymphoma, sarcoidosis, lung cancer and other thoracic entities. A case series
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment
por: Zarogoulidis, Paul, et al.
Publicado: (2017)